Tag
Bariatric surgery offers substantial 2-year weight loss for patients with obesity who experience intolerable side effects or inadequate response to semaglutide or tirzepatide, with Roux-en-Y gastric bypass demonstrating superior outcomes in
A systematic review and meta-analysis of 64 randomized trials reveals that GLP-1 receptor agonists lead to significantly higher weight loss in women (10.9%) compared to men (6.8%), while maintaining consistent efficacy across various ages,
A post hoc analysis of the SURMOUNT-4 trial reveals that withdrawing tirzepatide leads to significant weight regain and a proportional reversal of improvements in blood pressure, glycemic control, and lipid profiles, reinforcing the necessi
This article reviews recent evidence comparing weight loss outcomes and healthcare costs of bariatric surgery and GLP-1 receptor agonists, highlighting implications for clinical decision-making in treating class II and III obesity.
A recent trial comparing adaptive, algorithm-driven telephone support with static monthly coaching found no significant difference in long-term weight loss maintenance, highlighting complexities in obesity treatment and the need for refined
Digital health interventions show modest but clinically meaningful reductions in waist circumference for overweight and obese adults, highlighting their potential as adjuncts in obesity care despite limited effects on weight and behavior.
